HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Recommendation For OTC Buprenorphine Joins Opioid Abuse Epidemic Discussion

Executive Summary

Boston University researchers recommend allowing pharmacists to dispense buprenorphine without prescriptions to expand access among the 2m consumers with opioid use disorder and help reduce the estimated 130 overdose deaths each day in the US. "It is important to attempt to address the opioid epidemic in new, effective, and safe ways. Increasing access to buprenorphine, a relatively safe medication, without a prescription could prove helpful for treating persons with OUD," say Payel Jhoom Roy and Michael Stein.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS148984

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel